How much funding has Cellectis S.A. raised?

Cellectis S.A. has raised $300.0M in total funding, most recently a Corporate Round.

Who are Cellectis S.A.'s investors?

Cellectis S.A.'s investors include AstraZeneca, Pfizer Ventures.

When was Cellectis S.A. founded?

Cellectis S.A. was founded in 1999.

Where is Cellectis S.A. headquartered?

Cellectis S.A. is headquartered in Paris, France.

What industry is Cellectis S.A. in?

Cellectis S.A. operates in Biotech, Healthcare.

How many employees does Cellectis S.A. have?

Cellectis S.A. has 201-500 employees.

Cellectis S.A.

IPO

Home | Cellectis

Public · Paris, France · Founded 1999 · $300.0M raised

Biotech

Healthcare

Headquarters: Paris
Employees: 201–500
Founded: 1999
Business Model: B2B
Website: cellectis.com

Total Funding: $300.0M
Last Round: $140.0M Corporate RoundMay 2024
Rounds: 3
Type: Public

About

Founded in 1999, Cellectis is a clinical-stage biopharmaceutical company with 25 years of expertise in gene editing using its proprietary TALEN technology and PulseAgile electroporation system. The company pioneers allogeneic off-the-shelf CAR T-cell therapies (UCART) targeting cancers including B-ALL and non-Hodgkin lymphoma. Cellectis is listed on Nasdaq (CLLS) and Euronext Growth, with operations in Paris, New York, and Raleigh.

Summary

Cellectis S.A. is a Biotech company based in Paris, France, founded in 1999. It has raised $300.0M in total across 3 rounds, most recently a $140.0M Corporate Round round in May 2024. Investors include AstraZeneca and Pfizer Ventures.

LinkedIn X (Twitter)